Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Bristol-Myers (BMY), Incyte to Advance Clinical Program

Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

    Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals

    Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals

      5 Toxic Stocks to Get Rid Of or Play Short to Make Gains

      Exaggerated price of toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.

        Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?

        Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

          Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

            5 Toxic Stocks to Dump or Play Short to Make Gains

            Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.

              Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4

              Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.

                Sweta Killa headshot

                A Trip to 8-Year Bull Run: What's Up, What's Down

                While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.

                  5 Toxic Stocks to Abandon or Play Short Right Now

                  In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.

                    What's Driving Lilly's (LLY) Shares after 2016 Decline?

                    After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

                      Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

                      Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

                        Lilly's Olumiant Gets Marketing Authorization in Europe

                        Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

                          The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                          The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                            What's in Store for Avis Budget (CAR) this Earnings Season?

                            Avis Budget Group Inc. (CAR) is scheduled to report fourth-quarter 2016 results after market closes on Feb 15.

                              Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

                              Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

                                VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?

                                VASCO Data Security International Inc. (VDSI) is set to report fourth-quarter 2016 results after markets close on Feb 14.

                                  Should You Sell Incyte (INCY) Before Earnings?

                                  Incyte (INCY) looks like an exciting pick for investors as it is poised to beat at earnings season.

                                    Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

                                    Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

                                      Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?

                                      Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.

                                        5 Toxic Stocks to Dump or Play Short for Gains

                                        Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.

                                          Arpita Dutt headshot

                                          5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                                          Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.

                                            Can Prothena (PRTA) Pull a Surprise This Earnings Season?

                                            Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.

                                              Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

                                              Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                                                GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?

                                                GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.

                                                  Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?

                                                  Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.